Almirall, S.A. (VIE:ALM)

Market Cap	2.28B -5.1%
Revenue (ttm)	1.16B +9.8%
Net Income	59.13M +177.1%
EPS	0.28 +179.0%
Shares Out	n/a
PE Ratio	38.53
Forward PE	22.39
Dividend	0.15 (1.45%)
Ex-Dividend Date	May 14, 2026

Volume	n/a
Open	10.42
Previous Close	10.44
Day's Range	10.42 - 10.50
52-Week Range	10.28 - 13.84
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Pharmaceutical Preparations
• Founded: 1943
• Employees: 2,097
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ALM

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 3, 2026

Data Sources Report a data error